Form 4: Cellectar Biosciences Director John Neis Granted Stock Options Following Shareholder Approval

Director John Neis receives stock options after Cellectar Biosciences' shareholders approve the amended 2021 Stock Incentive Plan.

Summary

• John Neis, a director of Cellectar Biosciences, Inc., was granted stock options on June 14, 2024.
• The grant follows shareholder approval of Cellectar's amended 2021 Stock Incentive Plan at the company's 2024 Annual Meeting of Stockholders.
• Neis received options to purchase 60,000 shares of common stock at an exercise price of $2.58 per share.
• The options vest in full on December 22, 2024, contingent upon Neis' continued service through that date.
• The options expire on December 22, 2033.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their directors and officers.
• The size of the grant (60,000 shares) and the vesting schedule (full vesting after one year) appear to be within the typical range for director compensation in similarly sized biotech companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, Cellectar Biosciences, director, John Neis, shareholder approval, stock incentive plan, CLRB